As pemetrexed/cisplatin therapy has superior clinical benefits over other platinum-based doublet regimens4,5, and its chemotherapeutic outcomes are significantly associated with TS expression6,7, whether tumors express TS is an important issue in the management of non-squamous NSCLC. This evidence concerns the gene TYMS and non-small cell lung carcinoma.